Abstract:Background: Previous studies reported on the existence of atrophy-based Alzheimer's disease (AD) subtypes that associate with distinct clinical symptoms. However, the consistency of AD atrophy subtypes across approaches remains uncertain. This large-scale study aims to assess subtype concordance in individuals using two methods of data-driven subtyping. Methods: We included n=10,011 patients across the clinical spectrum from 10 AD cohorts across Europe, United States, and Australia, and extracted regional volumes using Freesurfer v7.1.1. To characterise atrophy heterogeneity in the AD continuum, we introduced a hybrid two-step approach called Snowphlake (Staging NeurOdegeneration With PHenotype informed progression timeLine of biomarKErs) to identify subtypes and sequence of atrophy-events within each subtype. We compared our results with SuStaIn (Subtype and Stage Inference) which jointly estimates both, and was trained and validated similarly. The training dataset included Aβ+ participants (n=1,195), and a control group of Aβ- cognitively unimpaired participants (n=1,692). We validated model staging within each subtype, in a held-out clinical-validation dataset (n=6,362) comprising patients across the clinical spectrum irrespective of Aβ biomarker status and an independent external dataset (n=762). Furthermore, we validated the clinical significance of the detected subtypes, in a subset of Aβ+ validation datasets with n=1,796 in the held-out sample and n=159 in the external dataset. Lastly, we performed concordance analysis to assess the consistency between the methods. Results: In the AD dementia (AD-D) training data, Snowphlake identified four subtypes: diffuse cortical atrophy (21.1%,age 67.5±9.3), parieto-temporal atrophy (19.8%,age 60.9±7.9), frontal atrophy (24.8%,age 67.6±8.8) and subcortical atrophy (25.1%,68.3±8.2). The subtypes assigned in Aβ+ validation datasets were associated with alterations in specific cognitive domains (Cohen's f: [0.15-0.33]), while staging correlated with Mini-Mental State Examination (MMSE) scores (R: [-0.51 to -0.28]) in the validation datasets. SuStaIn also identified four subtypes: typical (55.7%,age 66.7±7.8), limbic-predominant (24.2%,age 72.2±6.6), hippocampal-sparing (14.6%,age 62.8±6.9), and subcortical (0.8%,age 68.2±7.6). The subtypes assigned in Aβ+ validation datasets using SuStaIn were also associated with alterations in specific cognitive domains (Cohen's f:[0.17-0.34]), while staging correlated with MMSE scores in the validation datasets (R: [-0.54 to -0.26]). However, we observed low concordance between Snowphlake and SuStaIn, with 39.7% of AD-D patients consistently grouped in concordant subtypes by both the methods. Conclusion: In this multi-cohort study, both Snowphlake and SuStaIn identified four subtypes that were associated with different symptom profiles and atrophy-severity measures that were associated with global cognition. The low concordance between Snowphlake and SuStaIn suggests that heterogeneity may rather be a spectrum than discretised by subtypes.

Orbital cysticercosis ‐ an ultrasonic diagnosis

Gray matter structural covariance networks changes along the Alzheimer's disease continuum.

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease

Resolving heterogeneity in Alzheimer's disease based on individualized structural covariance network

Disentangling the heterogeneity of brain atrophy in Alzheimer’s Disease

Relationship between MRI brain-age heterogeneity, cognition, genetics and Alzheimer's disease neuropathology

Distinct Spontaneous Brain Activity Patterns in Different Biologically-Defined Alzheimer's Disease Cognitive Stage: A Preliminary Study.

Consistent genes associated with structural changes in clinical Alzheimer's disease spectrum

A Multimodal Meta-Analytical Evidence of Functional and Structural Brain Abnormalities Across Alzheimer's Disease Spectrum

Structure–function coupling reveals the brain hierarchical structure dysfunction in Alzheimer's disease: A multicenter study

Integrated multimodal cell atlas of Alzheimer’s disease

Integrated multimodal cell atlas of Alzheimer's disease

A large-scale multi-centre study characterising atrophy heterogeneity in Alzheimer's disease

Changes in functional and structural brain connectome along the Alzheimer’s disease continuum

Disentangling brain heterogeneity via semi‐supervised deep‐learning and MRI: Application to dimensional representations of Alzheimer’s disease

Joint signatures of morphological and microstructural inter-individual variation in the Alzheimer’s spectrum

Progressive structural and covariance connectivity abnormalities in patients with Alzheimer's disease

Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers

Longitudinal Volumetric Study for the Progression of Alzheimer's Disease from Structural MRI

A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data

Aberrant Connectivity in Mild Cognitive Impairment and Alzheimer Disease Revealed by Multimodal Neuroimaging Data.